Our Business News

Drugmakers AstraZeneca and Pfizer have a deal giving Pfizer future rights to sell a nonprescription version of AstraZeneca’s blockbuster heartburn drug, Nexium. Pfizer must first win approval from the Food and Drug Administration and regulators in other countries to sell nonprescription Nexium. The drug, which reduces excess stomach acid to treat ulcers and acid reflux disease, is known chemically as esomeprazole (eh-SO’-meh-preh-zohl). Pfizer said that if it wins approval, it could launch over-the-counter Nexium in the U.S. in 2014. The drug’s patent is slated to expire here that spring. Pfizer plans to begin selling the product in other countries after [...]

Pfizer Inc (PFE) said it would pay about $ 250 million to gain access to exclusive global rights for the over-the-counter version of British drugmaker AstraZeneca Plc’s (AZN) heartburn pill Nexium. AstraZeneca, which will continue to manufacture and market the prescription version of Nexium, would be eligible to get milestone and royalty payments from Pfizer based on the launch and sales of the drug. AstraZeneca would also supply Pfizer with the over-the-counter version of Nexium, upon marketing approval. The companies said they are also exploring the potential for a strategic partnership that could include similar agreements for other AstraZeneca prescription [...]

Pfizer Inc (PFE) said it would pay about $ 250 million to gain access to exclusive global rights for the over-the-counter version of British drugmaker AstraZeneca Plc’s (AZN) heartburn pill Nexium. AstraZeneca, which will continue to manufacture and market the prescription version of Nexium, would be eligible to get milestone and royalty payments from Pfizer based on the launch and sales of the drug. AstraZeneca would also supply Pfizer with the over-the-counter version of Nexium, upon marketing approval. The companies said they are also exploring the potential for a strategic partnership that could include similar agreements for other AstraZeneca prescription [...]

Pharmaceutic commercial operation Pfizer (NYSE: PFE) expelled Sunday a little arrange of recollect of merely a single trillion preventive bouts as a outcome of inconsistency inside of a medication. The tangible error, that customarily Pfizer seems to have associated to a little arrange of mechanised failure, competence presumably set females during interest meant for being profound as a outcome of variations in hormonal levels inside of a tablets. The tangible recollect impacts eighteen multiform Lo/Ovral-28 capsules along with eighteen multiform Norgestrel along with Ethinyl Estradiol tablets, a tangible concept indication in a medication. The tangible preventive is all marketed in a joined states by Akrimax Rx Companies [...]